Document Detail


ADHD Treatment and Pregnancy.
MedLine Citation:
PMID:  24794209     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
There is increasing recognition that ADHD is a common condition, not only in children and teenagers but also in adults. This has led to a rapid rise in the number of women of childbearing age who are being treated for this condition. Against the background of concerns about the use of medication of any kind during pregnancy and breastfeeding, it is remarkable that there is so little information available on the effects of ADHD medication on the fetus and newborn. The impulsivity associated with ADHD might lead to an increased rate of unplanned pregnancy. Although treating ADHD during pregnancy and lactation might have negative effects on the baby, suspension of treatment or inadequate treatment could also place both mother and baby at risk. Pharmacodynamic and pharmacokinetic changes during pregnancy could affect both the efficacy and the concentration of medication. Again, there is almost no guidance available. The US Food and Drug Administration has classified ADHD medications as being "pregnancy category C", implying that there is insufficient information to confirm either harm or lack of harm. From the limited information that has been published, it would appear that the risk of fetal malformation, at least with methylphenidate, is very low and that the amounts of medication excreted in breast milk and consumed by the infant are very small. Three questions that both clinicians and patients are likely to ask are the following. Should ADHD medication be stopped before, during or after pregnancy, or should it be continued throughout? Should ADHD medication doses be adjusted during the course of the pregnancy or after delivery? Should breastfeeding be encouraged or discouraged? Discontinuing ADHD treatment could put both mother and baby at risk. This has to be balanced against the possible risks to the baby of continuing treatment. Although the data remain inadequate, the risk of the latter appears to be quite small, at least for methylphenidate. However, there is recent evidence that the rates of fetal loss both through abortion and through miscarriage are increased with methylphenidate. Discussions about ADHD treatment with women of childbearing age should be balanced, open and honest, acknowledging the lack of information on the possible risks to the offspring of continuing treatment, while also drawing attention to the possible risks to both mother and child of discontinuing treatment.
Authors:
Frank M C Besag
Related Documents :
24528229 - The use of oral hypoglycaemic agents in pregnancy.
22378859 - Venous pulse transit time in normal pregnancy and preeclampsia.
19639459 - Fever in pregnancy and offspring mortality - a longitudinal study of a cohort from 1927...
16100639 - Perinatel outcomes of singleton pregnancies achieved by in vitro fertilization: a syste...
15198779 - Ultrasonographic occiput position in early labour in the prediction of caesarean section.
15295339 - Pregnancy outcomes after treatment for fibromyomata: uterine artery embolization versus...
406289 - The gray scale appearance of the normal pregnancy from 4 to 16 weeks of gestation.
6601799 - Fetal blood group studies during mid-trimester pregnancy and the management of severe i...
19560759 - Does dilation and curettage versus expectant management for spontaneous abortion in pat...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-5-3
Journal Detail:
Title:  Drug safety : an international journal of medical toxicology and drug experience     Volume:  -     ISSN:  0114-5916     ISO Abbreviation:  Drug Saf     Publication Date:  2014 May 
Date Detail:
Created Date:  2014-5-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9002928     Medline TA:  Drug Saf     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hip and low back pain in the presence of femoral anteversion. A case report.
Next Document:  Cardiotoxicity of systemic agents used in breast cancer.